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Abstract
Background: Management of prescription opioids misuse and abuse problems among chronic pain patients has
been increasingly important worldwide and little literature concerning prescription opioids can be found in
mainland China so far.
Methods: The Current Opioid Misuse Measure (COMM) was translated into Chinese following Brislin’s model of
cross-culture translation and was completed by a convenience sample of 180 patients with chronic pain recruited
from two major hospitals in Jinan, Shandong province. Data were analyzed using internal consistency, test-retest
reliability, exploratory factor analysis and confirmatory factor analysis.
Results: The internal consistency coefficient for the total score of the COMM was 0.85 and item-total correlations of
all items were above 0.20. Besides, the test-retest reliability was satisfactory with an ICC of 0.91 (95 % CI = 0.65-0.98).
Four principal components were extracted, accounting for 65.30 % of the variance, and the factor loadings of all 17
items were above 0.40.
Conclusions: The Chinese version of COMM showed satisfactory reliability and validity, and could be used as a
screening tool to evaluate and monitor current aberrant drug-related behavior among Chinese patients with
chronic pain.
Background
Opioids, as a potentially effective treatment for chronic
pain, have increasingly been prescribed for pain relief
among patients with chronic pain in recent years. Despite
the benefits of opioid therapy, opioid-related problems are
also increasing. In Australia, oxycodone prescriptions in-
creased, particularly among older patients [1]. In the United
States, prevalence of chronic opioid use increased from 3 %
in 2003 to 4.5 % in 2007, and multiple studies in the litera-
ture have reported an association between opioid prescrib-
ing and overall health status, with increased disability,
medical costs, subsequent surgery, and continued or late
opioid use [2]. Likewise, in Canada, according to available
data, the prescription opioid consumption levels were
increased and high. Correspondingly, its nonmedical pre-
scription opioid use and prescription opioid related harms
were high, and may now constitute the third highest level
of substance use burden of disease [3]. In addition, Dhalla
found that the prescribing of opioid analgesics in Ontario
increased by 29 %, from 458 to 591 prescriptions per 1000
individuals annually between 1991 and 2007, and the an-
nual number of opioid-related deaths increased by 41 %,
from 19.4 to 27.2 per million annually between 1999 and
2004 [4]. Therefore, identifying which patients under opioid
treatment may develop opioid-related aberrant behaviors is
important. Meanwhile, management of pain medication
misuse and abuse problems poses significant challenges.
However, in Mainland China, little is known about the pre-
scription opioids among chronic pain patients. From our
own experience as well as consulting clinical experts, we
get to know that opioids such as codeine, oxycodone, tram-
adol are often therapeutically prescribed for pain relief in
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China. However, physicians usually lay emphasis on pain
treatment, in view of the sever impairment both physically
and psychologically brought by chronic pain, like activity
limitation in daily life, depression, anxiety and anger, which
leads them to ignore the potential aberrant drug-related be-
haviors occurring during the process of pain treatment.
Therefore, such phenomenon arouse our attention and in-
spire our interests on conducting this research, with the
aim of introducing an opioid screening tool and investi-
gating the current status of aberrant drug-related be-
havior in Chinese patients with chronic pain.
“Misuse” is defined as use of the substance not accord-
ing to medical indications or prescribed dosing. In
addition, misuse is specifically restricted to the prescrip-
tion or over-the-counter medications, and it occurs only
when a drug is taken for medical purpose [5]. At present,
there are several ways available to help detect drug misuse,
such as urine drug testing (UDT), psychosocial screening
interviews and screening tools (self-report or clinician
rated) [6]. The screening tools were convenient, time-
saving and cost-effective, and therefore they were import-
ant and indispensable opioid monitoring methods. Among
these tools, the Screener and Opioid Assessment for Pa-
tients with Pain (SOAPP) was intended to be used at an
initial visit or when considering treatment with an opioid,
the Prescription Drug Use Questionnaire (PDUQ) and the
Pain Assessment and Documentation Tool (PADT) were
observational screening methods, the Opioid Risk Tool
(ORT) was susceptible to deception and fits validity is not
high. Finally, we chose the Current Opioid Misuse Meas-
ure (COMM) as the tool in our research [7–11].
The COMM was developed to assess current misuse
behaviors for patients with chronic pain who has been
on opioid therapy for an extended period of time. Ini-
tially, pain management and addiction specialists devel-
oped a 40-item alpha COMM using concept mapping,
which was then tested in 227 patients taking opioid for
chronic, noncancer pain and retested one week later
with 55 of them. Meanwhile, all participants finished the
Prescription Drug Use Questionnaire (PDUQ) as well as
urine drug testing for toxicity screening. Finally, 17
items demonstrated a capacity to measure aberrant be-
havior with good validity and reliability (Cronbach's α =
0.86; ICC = 0.86, 95 % CI: 0.77-0.92). The cutoff score of
the COMM was 9. Three months later, 86 patients were
re-assessed and showed adequate ability of the COMM
to track changes over time [12]. Furthermore, through
cross validation, Butler reported an excellent internal
consistency and validity of the COMM with a coefficient
alpha being 0.83 and an AUC of 0.79 (Standard error =
0.031; 95 % CI: 0.73-0.85) [13]. Meltzer found that the
sensitivity and specificity of the COMM were both 0.77
to identify patients with prescription drug use disorder
(PDD) when using the DSM-IV criteria for PDD as the
“gold standard” and the cutoff score was 13 [14]. It is a
useful tool for clinicians to periodically monitor misuse of
opioid medication and to develop treatment strategies in
order to minimize continued misuse [12]. Besides, current
practice guidelines recommend using the COMM to as-
sess patients receiving prescription opioid therapy [15].
The aim of this study was to: (1) translate the COMM
into Chinese; (2) investigate the reliability and validity of
the COMM among Chinese-speaking patients with
chronic pain; (3) determine whether the COMM can be
used in a Chinese population.
Methods
Participants and settings
Participants were recruited from pain clinics in two
major hospitals between July and October 2014 in Jinan
city, Shandong Province, China. The inclusion criteria
were: (1) age 18 years or older; (2) chronic pain for
3 months or longer; (3) prescription opioid medications
for 1 month or longer; and (4) ability to read and speak
Chinese with no significant or diagnosed cognitive prob-
lems. Ethical approval was obtained from the Research
Ethics Committees in Shandong University. In addition,
informed consent was obtained from each participant
and they had the right to choose whether they would
complete the survey independently or have the re-
searcher read the questions and record their responses.
The instrument
The COMM is a validated 17-item instrument, devel-
oped by Butler et al. to assess past-month aberrant
medication-related behaviors for pain patients taking
opioids [12]. A 5-point Likert scale ranging from 0
(never) to 5 (very often) is used for each item and the
COMM total score is the sum of the 17 items. As a self-
report screening instrument, the COMM provides an
estimate of the patients “current” status and its items
capture a 30-day period. It appears to be a reliable and
valid screening tool to monitor misuse behaviors among
chronic pain patients [13, 14]. Furthermore, Finkelman
et al. reported that curtailment and stochastic curtail-
ment of the COMM reduced its respondent burden
without compromising sensitivity and specificity [16].
Demographic information was obtained from the
questionnaire we designed to collect demographic and
pain-related information of the participants, including
age, sex, education, marital status, pain duration, months
of opioid treatment and pain location.
Translation process
Content licensing agreement was obtained from the ori-
ginal authors. The COMM was translated into Chinese,
following Brislin’s model [17, 18]. The translation of the
COMM from original English to Chinese (COMM-A and
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COMM-B) was first performed by two independent and
professional translators (A and B) in the research team.
The two translation versions (COMM-A and COMM-B)
were merged into one single forward translation version
(COMM-A/B) by a third professional and native speaker
(C). This version was translated back into Chinese by a
forth bilingual researcher (D) who had never seen the
scale previously. Discrepancies between the original
COMM and the back-translated version were reviewed for
equivalence of meaning. Lastly, the Chinese translation
version of COMM was modified and polished.
The translated COMM was pilot-tested on a conveni-
ence sample of twenty pain patients. After the test, new
problems concerning clarity, comprehension and inter-
pretability were discussed. For example, the “road rage”
was seldom used in China, many patients had difficulty
understanding this phrase, and then we discussed how
to express it more clearly and more comprehensible. Fi-
nally, the Chinese version COMM was obtained when
no substantial disagreements could be found, as is
shown in Table 1.
A panel of experts was invited to evaluate the content
equivalence of the COMM using content validity index
(CVI), which is a 4-point rating scale (1 = not relevant; 2 =
somewhat relevant; 3 = quite relevant; 4 = highly relevant).
The CVI is the percentage of agreement of all items rated
by the experts as either three or four and an ICC of 0.8 or
greater is generally considered to be an indication of good
content validity [19].
Statistical analyses
Statistical analyses were conducted using SPSS version
19.0 and Amos version 17.0. Statistical significance was set
at P < 0.05. For categorical variables, data were presented in
forms of frequencies and percentages, and continuous vari-
ables were reported as means ± standard deviation (SD).
The reliability of the COMM was assessed by internal
consistency and test-retest reliability. Specifically, the in-
ternal consistency reliability was determined by using
Cronbach’s alpha coefficients, corrected item-total correl-
ation and inter-item correlation matrix analysis. A Cron-
bach’s alpha of ≥0.70 and item-total correlation of >0.2
were deemed statistically acceptable [20]. The test-
retest reliability was evaluated by calculating the intra-
class correlation coefficients (ICC) using data from 10
patients who filled out the COMM within the 2-week
Table 1 Items of the Chinese version of COMM
Item
Number
English Items Items Translated Into Chinese
1 How often have you had trouble with thinking clearly or had memory problems? 思维不清或出现记忆方面的问题
2 How often do people complain that you are not completing necessary tasks? (i.e., doing things
that need to be done, such as going to class, work, or appointments)
周围的人抱怨您不能完成一些重要
的事情(例如上课、上班、约会等)
3 How often have you had to go to someone other than your prescribing physician to get sufficient
pain relief from your medications? (i.e., Another doctor, the Emergency Room)
为得到足量的止疼药而找其他的医
生或去急诊室
4 How often have you taken your medications differently from how they are prescribed? 不按照医嘱服用止疼药
5 How often have you seriously thought about hurting yourself? 有自残的想法
6 How much of your time was spent thinking about opioid medications (having enough, taking
them, dosing schedule, etc.)?
思考与止疼药有关的问题(例如是否
足够、怎样服用、剂量如何等)
7 How often have you been in an argument? 与别人争吵
8 How often have you had trouble controlling your anger (e.g., road rage, screaming, etc.)? 控制不住自己的脾气(例如交通阻塞
时产生愤怒情绪、大声争吵等)
9 How often have you needed to take pain medications belonging to someone else? 服用其他人的止痛药
10 How often have you been worried about how you’re handling your medications? 担忧自己服用止疼药的相关事宜(例
如服药方式、剂量等)
11 How often have others been worried about how you’re handling your medications? 令他人担忧自己服用止疼药的相关
事宜(例如服药方式、剂量等)




13 How often have you gotten angry with people? 迁怒于别人而发脾气
14 How often have you had to take more of your medication than prescribed? 服用止疼药的剂量超过医嘱的要求
15 How often have you borrowed pain medication from someone else? 借用别人的止疼药
16 How often have you used your pain medicine for symptoms other than for pain (e.g., to help
you sleep, improve your mood, or relieve stress)?
出于除疼痛之外的其他原因而服用
止疼药(例如催眠、改善情绪或减压)
17 How often have you had to visit the Emergency Room? 到医院急诊室就医
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interval. An ICC of 0.8 or higher was to be considered
acceptable [21].
Construct validity for the COMM was evaluated by
principal components analysis with Promax rotation.
We first conducted the Kaiser-Meyer-Olkin (KMO)
measure and Bartlett’s test to determine if there were a
statistically significant correlation among items to per-
form this analysis [22]. A value of 0.40 or greater for the
factor loadings was regarded as acceptable [23]. Further-
more, confirmatory factor analysis (CFA) was conducted
to compare the hypothesized factor structure with the re-
search data. Specifically, various well-established model fit
indices including Chi square test, Chi square/df ratio, root
mean square error of approximation (RMSEA), compara-
tive fit index (CFI), incremental fit index (IFI), Tucker-
Lewis index (TLI), root of the mean square residual
(RMR), goodness-of-fit index (GFI), and adjusted GFI
(AGFI) were used to assess the model fit.
Results
Sample characteristics
The 180 chronic pain patients (155 non-cancer and 25
cancer pain patients) had an average age of 55.74 years
(SD 16.36), with a range of 18–88 years, and 52.22 %
were male. Overall, seventy four patients (41.11 %) had
received more than nine years’ education and 155 partic-
ipants (86.11 %) were married. The average duration of
pain was 27.08 months (SD = 52.42), with a range of 3–
360 months. The most common primary pain locations
were lumbar or sacral pain (38.33 %) and leg pain
(35.00 %), as is shown in Table 2.
Reliability
The Cronbach’s alpha and the corrected item-total cor-
relations of all 17 item are shown in Table 3. The in-
ternal consistency coefficient (Cronbach’s α) for the total
score of the COMM was 0.85. Item-total correlations
ranged from 0.24 (item 9) to 0.62 (item 14) and all items
met the recommended minimum of 0.20. In addition, as
is shown in Table 4, some items showed poor or nega-
tive inter-item correlation, suggesting that COMM may
not be a unidimensional measurement.
Moreover, of the 180 participants, 10 were randomly
selected to evaluate the teat-retest reliability in two
weeks’ interval. The mean scores of the first and second
measurements were 13.37 ± 8.15 and 17.80 ± 4.92, re-
spectively. The test-retest reliability was satisfactory with
an ICC of 0.91 (95 % CI = 0.65-0.98).
Validity
For the COMM, all of the 17 items showed a CVI above
0.8, which indicates that the construct validity of the
COMM was acceptable.
The construct validity of the COMM was deter-
mined by principal components factor analysis with
Promax rotation. The result of the KMO measure
was 0.78, and the approximate chi-square for Bar-
tlett’s test was 1390.099 (df = 136, P < 0.001). As
shown in Table 5, the factor loadings of all 17 items
ranged from 0.42 (item 5) to 0.96 (item 8). Four prin-
cipal components were extracted with eigenvalue of
4.97, 2.51, 1.98 and 1.63, respectively. Variables 5, 7,
8 and 13 load on factor 1; 3, 4, 9, 14 and 15 load on
factor 2; 1, 2, 12, 16 and 17 load on factor 3; and 6,
10 and 11 load on factor 4. The percent variances for
the four factors were 29.25, 14.79, 11.65 and 9.61 %,
respectively.
CFA was performed to test the four-factor model,
and the results showed that it did not exhibit accept-
able fit indexes. Then modification was made to im-
prove the fit. Finally, an acceptable model fit was set,
with a four-factor structure. The modified four factors
Table 2 Demographic characteristics of the participants (n = 180)
Characteristics n (%) Mean (SD) Median





≤1 year 21 (11.67)
≤5 years 27 (15.00)
≤9 years 58 (32.22)






Pain duration (months) 27.08 (52.42) 5.00
Months of opioid treatment 8.83 (30.35) 2.00
Pain locations
Head, face 22 (12.22)
Cervical 24 (13.33)




Lumbar, sacral 69 (38.33)
Pelvic 29 (16.11)
Leg 63 (35.00)
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were: Factor 1 (item 5, 7, 8 and 13), Factor 2 (item 4,
9, 14 and 15), Factor 3 (item 1, 2, 3, 12, 16 and 17),
and Factor 4 (item 6, 10 and 11). According to the
findings from the CFA, which are shown in Table 6,
the model fitting was acceptable [24].
Discussion
To our knowledge, this study is the first to apply screen-
ing tool of opioid medication to assess aberrant drug-
related behaviors in chronic pain patients in Mainland
China. Besides, it also provides the first report on the
translation and validation of the COMM into Chinese
language. The results in this study show good qualities
of the COMM in terms of content, interpretability and
acceptability. We are able to show feasibility for the use
of the Chinese version of COMM to measure misuse be-
haviors of prescription opioid among patients with
chronic pain.
The Cronbach’s coefficient alpha of the Chinese ver-
sion of COMM exceeded 0.70, the general requirements
of a questionnaire internal consistency. This value was
approximately equal to that of the original English ver-
sion [12]. The item-total correlations reached the gen-
eral requirement of 0.20. In addition, ‘Cronbach’s alpha if
item deleted’ showed that when an item was deleted
from the COMM, the total questionnaire Cronbach’s co-
efficient alpha would not significantly changed, which
suggests that its items had good internal consistency re-
liability. Besides, at an individual questionnaire level,
some items do not correlate well with each other. It
might be due to the fact that according to the original
version, all 17 items came from five clusters identified
through the concept mapping process. With regard to
test-retest reliability, the ICC value for the COMM
reached more than 0.80, indicating good agreement.
And the ICC value in our study was higher than the
Table 3 Mean scores, corrected item-total correlations of the
Chinese version of COMM




1 0.70 0.94 0.38 0.84
2 0.62 0.92 0.52 0.83
3 0.40 0.77 0.30 0.84
4 0.54 0.75 0.52 0.83
5 0.34 0.71 0.53 0.83
6 1.15 1.07 0.38 0.84
7 0.92 0.86 0.54 0.83
8 1.21 1.04 0.54 0.83
9 0.17 0.52 0.24 0.84
10 0.97 1.03 0.42 0.84
11 0.77 0.95 0.53 0.83
12 0.23 0.61 0.42 0.84
13 1.15 1.11 0.57 0.83
14 0.57 0.89 0.62 0.83
15 0.12 0.39 0.29 0.84
16 0.35 0.71 0.45 0.84
17 1.83 1.45 0.52 0.84
Table 4 Correlation matrix of COMM items
Item 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
1 1
2 0.65** 1
3 0.10 0.19* 1
4 0.13 0.25** 0.27** 1
5 0.24** 0.41** 0.19** 0.27** 1
6 0.12 0.17* 0.22** 0.23** 0.24** 1
7 0.24** 0.26** 0.05 0.22** 0.34** 0.10 1
8 0.22** 0.27** 0.04 0.30** 0.39** 0.09 0.76** 1
9 −0.07 0.03 0.44** 0.27** 0.18* 0.11 0.07 0.06 1
10 0.08 0.20** 0.11 0.14 0.29** 0.67** 0.17* 012 0.11 1
11 0.20** 0.35** 0.24** 0.24** 0.27** 0.50** 0.25** 0.21** 0.17* 0.70** 1
12 0.33** 0.26** 0.20* 0.24** 0.20** 0.10 0.28** 0.29** 0.03 0.07 0.16* 1
13 0.26** 0.26** −0.01 0.33** 0.40** 0.13 0.73** 0.84** 0.05 0.15 0.24** 0.29** 1
14 0.14 0.28** 0.36** 0.69** 0.33** 0.22** 0.29** 0.34** 0.39** 0.22** 0.30** 0.33** 0.39** 1
15 −0.01 0.05 0.34** 0.38** 0.16* 0.09 0.07 0.07 0.60** 0.12 0.20* 0.07 0.04 0.51** 1
16 0.260** 0.40** 0.28** 0.36** 0.33** 0.25** 0.13 0.03 0.23** 0.24** 0.250** 0.28** 0.11 0.48** 0.24** 1
17 0.32** 0.38** 0.11 0.34** 0.27** 0.15* 0.41** 0.41** 0.01 0.20** 0.27** 0.38** 0.43** 0.42** 0.05 0.25** 1
*P < 0.05. **P <0.01
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result reported by Butler et al. These findings demon-
strate that the Chinese version of COMM is a reliable
brief measure for assessing aberrant drug-related
behavior.
The CVI was excellent, showing that all seventeen items
evaluate the same construct as an overall instrument. In
the original article of the COMM development, all the 17
items came from five clusters generated during the brain-
storming stage, they are: (1) Signs & Symptoms of Drug
Misuse (item 1); (2) Emotional Problems/Psychiatric Issues
(item 2, 5, 7, 8 and 13); (3) Appointment Patterns (item 3,
12 and 17); (4) Evidence of Lying and Drug Use (item 4, 6,
9, 10 and 11); (5) Medication Misuse & Noncompliance
(item 14, 15 and 16) [12]. According to the results of factor
analysis, all the 17 items of the COMM were grouped into
the four factors, with factor loadings reaching the criteria of
0.40. It showed that the construct of the Chinese version of
COMM did not keep in with what originally intended. Spe-
cifically,the first factor was labeled emotional or psychiatric
problems (item 5, 7, 8 and 13), the second was medication
misuse or noncompliance (item 4, 9, 14 and 15), the third
was memory and doctor visit (item 1, 2, 3, 12, 16 and 17),
and the fourth was apprehension of drug use (item 6, 10
and 11). These factors indicated the four possible under-
lying dimensions of the COMM and these factors explained
65.30 % of the variance. According to the two-index pres-
entation format suggested by Hu and Bentler, when
RMSEA was 0.06 or lower and SRMR was 0.09 or lower,
the model fit was acceptable. The fitting indexes from CFA
fully proved that the model fitting was acceptable [24].
Although, aberrant drug-related behaviors occurring
during the process of opioid treatment have increasingly
been social and ethical problems for us to deal with, it is
important to note that the COMM is not meant to be used
punitively, or to deny access to pain relief. It is just one
measurement to assess potential opioid misuse for patients
on opioid therapy, with the aim of achieving the best opi-
oid treatment effect and then improving the quality of life.
There are several limitations in the present study. The
researchers in our research team, the funds we got, and
the time of conducting this study were all limited, so the
sample was recruited only from two major hospitals in
Jinan city, Shandong province, in which the pain clinics
were ones with relatively larger scale. The two hospitals
we chose were both tertiary A hospitals and located in
urban area. In addition, all the patients in the present
study were not selected randomly, and 65.14 % of them
came from cities, the most common primary pain loca-
tions were lumbar or sacral and leg pain, accounting for
73.33 %, and codeine, oxycodone, tramadol were more
used prescription opioids. Therefore, the findings may not
be extrapolated to the general chronic pain patients. Fur-
ther studies from diverse populations across geographic
locations are needed for generalization of the findings to
the whole chronic pain patients taking prescription opioid.
Moreover, criterion validity of the COMM was not ana-
lyzed, since no Chinese version tools, which could be used
as proper “criterion” to assess participants' drug misuse
behaviors, could be found. However, other methods in-
cluding UDT and psychosocial screening interviews, could
be used as references in combination with the Chinese
version of COMM to evaluate its predictive and diagnostic
capabilities in further studies. Besides, because limitations
of time, financial and human resources, the sample size
for a test-retest reliability testing was quite small, and the
sample size for the CFA is not big as well. Further research
should recruit a much larger sample to verify our research
findings. Last but not least, other screening tools for aber-
rant drug-related behaviors, either self-report or physician
rated, such as the pain medication questionnaire (PMQ),
screener and opioid assessment for patients with pain
(SOAPP), opioid risk tool (ORT), prescription drug use
questionnaire (PDUQ) and pain assessment and docu-
mentation tool (PADT) [7–11, 25], should also be in-
troduced, explored and compared with the COMM in
Table 5 Factor analysis results for the Chinese version of COMM
Item Factor 1 Factor 2 Factor 3 Factor 4
8 0.96 −0.04 −0.06 −0.03
13 0.94 −0.02 −0.05 0.05
7 0.88 −0.06 0.01 0.01
5 0.42 0.16 0.18 0.15
15 −0.50 0.86 −0.22 −0.05
9 −0.51 0.84 −0.24 0.02
14 0.23 0.73 0.10 −0.03
4 0.20 0.63 0.12 −0.01
3 −0.26 0.63 0.19 0.04
1 −0.05 −0.26 0.91 −0.04
2 −0.04 −0.10 0.88 0.07
12 0.13 0.12 0.55 −0.15
16 −0.22 0.38 0.53 0.08
17 0.22 0.18 0.50 −0.06
10 0.05 −0.08 −0.09 0.97
6 −0.06 0.01 −0.04 0.87
11 0.05 0.06 0.08 0.80
Eigenvalue 4.97 2.51 1.98 1.63
Percent variance (%) 29.25 14.79 11.65 9.61
A value of 0.40 or greater for the factor loadings was regarded as acceptable
Table 6 Results of the confirmatory factor analysis
Χ2 Χ2/df RMSEAa CFIa IFIa TLIa RMRa GFIa AGFIa
250.08 2.55 0.05 0.88 0.90 0.91 0.06 0.93 0.90
aRMSEA, root mean square error of approximation; CFI, comparative fit index;
IFI, incremental fit index; TLI, Tucker-Lewis index; RMR, root of the mean square
residual; GFI, goodness-of-fit index; AGFI, adjusted GFI
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their properties and characteristics in order to provide
a more effective and efficient way for management of
pain medication.
Conclusions
In conclusion, this is the first attempt to translate and
validate the COMM in a non-English-speaking country.
As reported in this study, the Chinese version of COMM
demonstrated relatively high level of reliability and validity
among Chinese patients with chronic pain. This self-
report measure could evaluate and monitor current aber-
rant drug-related behavior as a screening tool among
Chinese patients with chronic pain-prescribed opioids.
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